Table 1 Clinical and biochemical characteristics of the included clinical trials
Author | Study design | Target Population | Treatment duration | n | Study groups |
|---|---|---|---|---|---|
Boczar et al. 2022 [33] | Prospective randomized trial | HIV infection | 6 months | 17 18 | Rosuvastatin 10 mg/day Control |
Emami et al. 2015 [34] | Open-label trial | History of atherosclerosis | 3 months | 24 24 | Atorvastatin 80 mg/day Placebo |
Ishii et al. 2010 [42] | Randomized, open-label trial | Adults with stable angina pectoris | 6 months | 15 15 | Atorvastatin 5 mg/day Atorvastatin 20 mg/day |
Kim et al. 2020 [35] | Prospective interventional study | Acute coronary syndrome | 1 month | 13 | Atorvastatin 20 mg/day |
Lo et al. 2015 [36] | Randomized, double-blind, placebo-controlled | HIV-infected patients | 1 year | 17 20 | Atorvastatin 40 mg/day Placebo |
Subramanian et al. 2013 [37] | Randomized, double-blind, active-controlled | Adults with risk factors or with established atherosclerosis | 3 months | 29 29 | Atorvastatin 10 mg/day Atorvastatin 80 mg/day |
Tawakol et al. 2013 [38] | Randomized, double-blind trial | Individuals with arterial inflammation | 3 months | 34 34 | Atorvastatin 10 mg/day Atorvastatin 80 mg/day |
van der Valk et al. 2016 [41] | Open-label trial | Patients with ankylosing spondylitis | 3 months | 18 | Atorvastatin 40 mg/day |
Watanabe et al. 2015 [39] | Randomized, open-label trial | Patients with hyperlipidemia | 6 months | 10 10 | Pitavastatin 2 mg/day Pravastatin 10 mg/day |
Wu et al. 2012 [40] | Open-label trial | Patients with atherosclerosis | 3 months | 43 34 | Atorvastatin 40 mg/day Control |